Biologics, including tumor necrosis factor (TNF) inhibitors (e.g., infliximab, adalimumab) and interleukin inhibitors, have significantly improved the treatment landscape for IBD [12]. The gene discussed is TNF; the disease is inflammatory bowel disease.